Senzime AB
The answer first
Does Senzime beat the market?
No, Senzime has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 18% of Nordic stocks
- Quality73
- Value14
- Trend14
No. 136 of 195 in healthcare
Max for seven days
Follow Senzime with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Senzime
Your first answer is free, no account needed.
Do you own Senzime, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Senzime and a few more. Free, no card.
Super Stock+44.6%In short
- Senzime has fallen 33.2% over the past year, including dividends.
- Overall, Senzime ranks better than 18% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.2%. The price is 87.2% below its peak now.
What do analysts think of Senzime?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 18% of Nordic stocks.
No. 136 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 75 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.11
- Asset turnoverSales divided by everything the company owns0.34
- Return on equityProfit divided by equity−38.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 122 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.0
- P/SPrice divided by sales4.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 146 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−13.0%
- 6 months−26.9%
- 9 months−33.1%
- 12 months−33.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Senzime
6 funds we follow own Senzime. The share is how much of the fund the stock makes up.
- Sweden6
From the funds' latest known holdings.
About Senzime
Senzime AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 59 employees.
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe.


See the full analysis of Senzime.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card